IP Library Granted Patent US 8,426,428
Granted Patent B2
US 8,426,428 · App. 12/329,445 · Granted Apr 23, 2013

EGFR kinase knockdown via electrophilically enhanced inhibitors

Inventor: Richard Miller (Portola Valley, CA)
Assignee: Principia Biopharma, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,426,428
App. No.
12/329,445
Granted
Apr 23, 2013
Kind
B2
Abstract

Provided herein are electrophilically enhanced kinase inhibitors of Formula I. Also provided herein are methods of making and utilizing the same.

Claims (75)

1. A compound of Formula I:

wherein:

each R 1

and R 2 is H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, C(═O)R 5 or C(═NR 5 ); wherein R 5 is H, hydroxy, substituted or unsubstituted alkyl or substituted or unsubstituted alkoxy;

each R 3 is independently H, halo, hydroxy, CN, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, or substituted or unsubstituted heteroalkyl;

each R 4 is independently substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl;

W is —CH 2 —, —C═C—, O, S, or NR 1 ;

n is 1-7

Q 1 is N;

Q 2 is N;

L is A p , wherein

each A is independently NR 1 , S(O) q , O, C(═X)Y, Y(C═X), substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl; wherein each q is independently 0-2;

p is 0-5;

E is an electrophile selected from:

—(CR 14 R 15 ) r —(CR 8 ═CR 8 ) q —(CR 14 R 15 ) r —

wherein

R 14 and R 15 are independently H, CN, NO 2 , substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or taken together are ═S, ═N —OR 11 , or ═O; wherein each R 11 is independently substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroalkyl;

each R 8 is independently H, halo, hydroxy, alkoxy, cyano, nitro, S(O) 1-2 R 11 , —C(═X)YR 11 , —YC(═X)R 11 , substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heteroalkyl, or two R 8 are taken together to form a bond;

each r is independently 0-2;

q is 1-2;

Z is —(Z 1 ) k —Z 2

Z 1 is NR 6 , O, C(═X)Y, Y(C═X), substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl

Z 2 is H, NR 6 2 , S(O) q R 6 , OR 6 , —C(═X)YR 6 , —Y(C═X)R 6 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl;

each R 6 is independently H, halo, hydroxy, alkoxy, cyano, nitro, —C(═X)YR 7 , —YC(═X) R 7 , substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroalkyl, wherein R 7 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroalkyl;

k is 0-4;

each X is independently S or O;

each Y is independently S or O;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein E is an electrophile subject to nucleophilic substitution or nucleophilic addition when contacted with a thiol or thiolate.

3. The compound of claim 1 , wherein R 1 and R 2 are independently H or substituted or unsubstituted alkyl.

4. The compound of claim 1 , wherein R 3 is H, halo, substituted or unsubstituted alkyl, or substituted or unsubstituted alkoxy.

5. The compound of claim 1 , wherein W is —CH 2 —or O.

6. The compound of claim 1 , wherein n is 1-3.

7. The compound of claim 1 , wherein E is —(C═O)—(CH═CH)—, —(CH═CH)—(C═O)—, —C(CN)═CH—, —CH═C(CN)—, —C(NO 2 )═CH—, or —CH═C(NO 2 .

8. The compound of claim 1 , wherein n is 1 or 2, and wherein one A is tetrahydroquinolinyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, phenyl, cyclohexyl, cyclopentyl, pyridinyl, pyrimidinyl, piperidinyl, homopiperidinyl, pyrrolidinyl, piperazinyl, or morpholino.

9. The compound of claim 1 , wherein Z 2 is NR 6 2 , substituted or unsubstituted heteroalkyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperazinyl or a substituted or unsubstituted morpholino.

10. The compound of claim 1 , wherein R 4 is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

11. The compound of claim 1 having the Formula II:

wherein

R 3 is H, halo, substituted or unsubstituted alkyl or substituted or unsubstituted alkoxy;

R 4 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl;

R 14 is H;

R 15 is H; or R 14 and R 15 taken together are ═O;

R 8a is H, lower alkyl, CN, NO 2 , or SO 2 R 11 ; and

R 8b is H, CN, NO 2 , or SO 2 R 11 .

12. The compound of claim 11 , wherein R 14 and R 15 taken together are ═O, and wherein R 8a and R 8b are H.

13. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I:

wherein:

each R 1

and R 2 is H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, C(═O)R 5 or C(═NR 5 ); wherein R 5 is H, hydroxy, substituted or unsubstituted alkyl or substituted or unsubstituted alkoxy;

each R 3 is independently H, halo, hydroxy, CN, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, or substituted or unsubstituted heteroalkyl;

each R 4 is independently substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl;

W is —CH 2 —, —C═C—, O, S, or NR 1 ;

n is 1-7

Q 1 is N;

Q 2 is N;

L is A p , wherein

each A is independently NR 1 , S(O) q , O, C(═X)Y, Y(C═X), substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl; wherein each q is independently 0-2;

p is 0-5;

E is an electrophile selected from:

—(CR 14 R 15 ) r —(CR 8 ═CR 8 ) q —(CR 14 R 15 ) r —

wherein

R 14 and R 15 are independently H, CN, NO 2 , substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or taken together are ═S, ═N—OR 11 , or ═O; wherein each R 11 is independently substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroalkyl;

each R 8 is independently H, halo, hydroxy, alkoxy, cyano, nitro, S(O) 1-2 R 11 , —C(═X)YR 11 , —YC(═X)R 11 , substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heteroalkyl, or two R 8 are taken together to form a bond;

each r is independently 0-2;

q is 1-2;

Z is —(Z 1 ) k —Z 2

Z 1 is NR 6 , O, C(═X)Y, Y(C═X), substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl

Z 2 is H, NR 6 2 , S(O) q R 6 , OR 6 , —C(═X)YR 6 , —Y(C═X)R 6 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl;

each R 6 is independently H, halo, hydroxy, alkoxy, cyano, nitro, —C(═X)YR 7 , —YC(═X) R 7 , substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroalkyl, wherein R 7 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroalkyl;

k is 0-4;

each X is independently S or O;

each Y is independently S or O;

or a pharmaceutically acceptable salt thereof;

and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2009
From: MILLER, RICHARD
To: PRINCIPIA BIOPHARMA, INC.
Reel/Frame 022056/0879 →
Continuity (1)
Related Publication 20100144705A1 · Jun 10, 2010